EUVIMEDEUVIMED entdecken
Fallbericht

Anifrolumab in Refractory Juvenile Dermatomyositis

Amaia Barrutia-Etxebarria iD, Rosa María Escribano De La Torre, Jone Lopez Martinez, Juan Ramón De Dios Jimenez de Aberasturi, Zuriñe Martinez de Lagrán Álvarez de Arcaya

Pediatric Dermatology · 2026-01 · 43 (1) · 116-120

DOI: 10.1111/pde.16012 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Dermatology, online erschienen am 17.07.2025. Verfasst von Amaia Barrutia-Etxebarria und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain. Hauptthemen laut MEDLINE: Dermatomyositis, Antibodies, Monoclonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile dermatomyositis (JDM) is a rare, idiopathic inflammatory myopathy of childhood and first‐line therapy typically includes corticosteroids and immunosuppressive agents, but complete and sustained remission of the disease is not always achieved. This case report describes an 8‐year‐old girl with refractory JDM who failed multiple therapies, including corticosteroids, disease‐modifying agents, and JAK inhibitors. After the introduction of anifrolumab, a monoclonal antibody targeting the type I interferon receptor, the patient experienced significant improvement in both skin and muscle symptoms. Her disease activity scores decreased markedly, and the response was sustained over six months with no adverse effects. This is the third reported case of JDM treated with anifrolumab, highlighting the potential of targeting the type 1 interferon pathway as a promising therapeutic strategy for patients with refractory disease. The case underscores the importance of IFN‐I dysregulation in dermatomyositis and the value of blocking this pathway in difficult‐to‐treat cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisAntibodies, MonoclonalHumansChildFemaleAntibodies, Monoclonal, HumanizedTreatment Outcome

Stichwörter der Autor:innen

anifrolumabjuvenile dermatomyositistype 1 interferon pathway

Substanzen

Antibodies, Monoclonal, HumanizedanifrolumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
  • Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.

ORCID-Profile: Amaia Barrutia-Etxebarria

Zitieren

APA

Barrutia-Etxebarria, A., Escribano De La Torre, R. M., Lopez Martinez, J., De Dios Jimenez de Aberasturi, J. R., & Martinez de Lagrán Álvarez de Arcaya, Z. (2026). Anifrolumab in Refractory Juvenile Dermatomyositis. Pediatric Dermatology, 43(1), 116-120. https://doi.org/10.1111/pde.16012

Vancouver

Barrutia-Etxebarria A, Escribano De La Torre RM, Lopez Martinez J, De Dios Jimenez de Aberasturi JR, Martinez de Lagrán Álvarez de Arcaya Z. Anifrolumab in Refractory Juvenile Dermatomyositis. Pediatric Dermatology. 2026;43(1):116-120. doi:10.1111/pde.16012

BibTeX
@article{BarrutiaEtxebarria2026,
  author = {Barrutia-Etxebarria, Amaia and Escribano De La Torre, Rosa María and Lopez Martinez, Jone and De Dios Jimenez de Aberasturi, Juan Ramón and Martinez de Lagrán Álvarez de Arcaya, Zuriñe},
  title = {Anifrolumab in Refractory Juvenile Dermatomyositis},
  journal = {Pediatric Dermatology},
  year = {2026},
  volume = {43},
  number = {1},
  pages = {116--120},
  doi = {10.1111/pde.16012}
}
Kostenlos starten →